Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Sponsored by UCB

Feb 19, 2025 11:00 am

Presentation

Alice Gottlieb, M.D.

Author(s):

Diamant Thaçi, Akihiko Asahina, Wolf‑Henning Boehncke, Alice B. Gottlieb, Mark Lebwohl, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola

Abstract or description:

This study aimed to assess the efficacy and safety of bimekizumab (BKZ) to 2 years in patients with psoriatic arthritis (PsA) who also had skin and nail psoriasis, and were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had prior inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

These studies were funded by UCB. All costs associated with development of this presentation were funded by UCB.

Time to Clinical Response to Secukinumab Across Disease Domains Among Patients With Psoriatic Arthritis: a Pooled Post Hoc Analysis of 4 Phase 3 Trials

Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-Year Final Results of a Prospective Real-World Study

Real-world outcomes in patients with RA remaining on first-line TNFi

Long-term maintenance of response of an IL-23i in PsA